Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

Novartis bought Alcon from Nestlé for $52 billion in 2011, as CEO Joe Jimenez, guided by then chairman Vasella, sought to build the company into a European healthcare business following the model ...

At a signing ceremony Wednesday in Zurich, pharmaceutical giant Novartis finally closed a deal to take over a 77 percent stake in eyecare company Alcon held by Nestle. Novartis’s quest had ...

Alcon Inc. (NYSE:ALC) is a Novartis spin off that is one of the biggest eye care products providers in the world. Its size ...

TPG-backed ophthalmology specialist BVI Medical will use the investment to fund new product launches and scale its operations ...

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments ...

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments ...

ZURICH (Reuters) - Novartis AG wrapped up its long-awaited buyout of the remainder of U.S.-listed eyecare group Alcon Inc for $12.9 billion, after sweetening its original offer with cash. The Swiss ...

“We’re testing prototypes that can generate a reading once per second.” Six months later, Alcon, Novartis’s eye care unit, has licensed the technology from GoogleX, the research division within the ...

UBS Group, Zurich Insurance Group, Holcim, Swiss Re, Alcon, Novartis and Julius Baer closed higher by 0.3 to 0.85%. Shares of dermatology company Galderma climbed about 1.7%, lifted by an ...